Brava Diagnostics Email Format
Medical Equipment ManufacturingColorado, United States2-10 Employees
Brava Diagnostics is developing a highly sensitive in vitro diagnostic point-of-care platform for the acute care market. The Company is seeking financing to fund product development for rapid multiplex tests for emergency medicine and critical care. Our first product will be a high-sensitivity troponin test for diagnosis of heart attack. THE NEED Emergency physicians need precise lab results, ideally within 15 minutes, to guide treatment or safe discharge for patients with chest pain. New guidelines from the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) are driving the shift to high-sensitivity troponin assays (hs-cTn). Central lab tests suffer from turnaround time of more than an hour. Point-of-care (POC) assays are widely used, but the, care team must compromise performance for speed. Neither lab nor POC tests meet the need. OUR SOLUTION Brava can fill this large market gap with a high-sensitivity troponin test that delivers lab-quality performance at the point-of-care in 15 minutes. Our evanescent planar waveguide technology is a different approach to POC diagnostics that enables a low-cost instrument and high margin consumable cartridges. The platform enables precise measurements at very low concentrations. MBio developed the core technology over ten years and has commercialized products outside of human health, significantly de-risking product development. Brava will build on these accomplishments by adapting the instrument for the healthcare market, developing in vitro diagnostic assays and executing clinical trials. Visit BravaDx.com to view videos and learn more about the markets, drivers and our products.
1-888-653-2347 
support@leadiq.com 
